Semaglutide has an elimination half-life of roughly one week. That single pharmacokinetic fact drives almost everything patients experience after their final dose — and it's why discontinuation is a gradual physiological unwinding rather than an overnight switch.
Key Takeaways
- Semaglutide's ~7-day half-life means meaningful drug levels persist for 4–5 weeks after the last injection.
- Appetite and 'food noise' typically return gradually between weeks 2 and 6.
- Extension studies of major trials found participants regained a substantial portion of lost weight within a year of stopping without lifestyle support.
- Physicians increasingly plan discontinuation months in advance rather than treating it as an endpoint.
Weeks 1–2: Still Effectively Medicated
With a one-week half-life, your serum concentration at day 7 is about half of steady state, and at day 14 roughly a quarter. Most patients notice little change in the first two weeks. Appetite suppression persists, meal sizes stay small, and gastric emptying remains slowed. This window is deceptive — patients often conclude discontinuation will be easy based on how these weeks feel.
Weeks 3–4: The First Real Shifts
As drug levels fall below the therapeutic range, gastric emptying normalizes first. Patients report feeling hungry sooner after meals and being able to eat larger portions comfortably. Hunger hormones that were suppressed begin recovering toward baseline. This is typically when "food noise" — intrusive thoughts about eating — starts to reappear for the patients who had it before treatment.
Weeks 5–8: Baseline Appetite Returns
By the end of week 5 the drug is essentially cleared. Appetite regulation now runs entirely on your own physiology — which, importantly, is the physiology of a body that has lost weight. Weight loss itself lowers leptin and raises ghrelin, a combination that biases the system toward regain. This is not a personal failing; it is well-documented metabolic adaptation, and it's the core reason extension studies show regain after discontinuation.
Months 3–12: The Trajectory Question
Published extension data from major semaglutide trials showed participants regained, on average, a majority of their lost weight within a year of stopping — though with wide individual variation. Patients who maintained resistance training, protein intake, and structured eating habits regained substantially less. The clinical takeaway: what you build during treatment determines what happens after it.
What Physicians Actually Monitor After Discontinuation
A well-run discontinuation plan includes a weight check cadence (typically monthly for six months), repeat labs at 3–6 months if A1C or lipids were elevated pre-treatment, and an explicit re-start criterion agreed in advance — for example, regain of more than a defined percentage of lost weight. Knowing the re-start plan removes the shame spiral if regain begins.
If You're Planning to Stop — or Restart
If cost drove the decision, know that compounded pricing has fallen dramatically in 2026. Several supervised programs now cost less per month than many patients' original copays:
Telos Rx — Semaglutide
Compounded semaglutide — from $49/mo on 12-month plans
Same flat-at-every-dose structure on the semaglutide side: $199 month-to-month, $129 quarterly, $99 semi-annual, $49/mo annual.
Compounded medications are not FDA-approved.
Visit Telos Rx Paid linkGala
Injectable — $179/mo flat, every dose
One flat price at every dose level, which removes the dose-increase billing surprise entirely.
Compounded medications are not FDA-approved.
Visit Gala Paid linkWellorithm
Oral tablets — sema $147/mo, tirz $249/mo
Among the lowest published oral compounded prices we track, with tablet formats for both semaglutide and tirzepatide.
Compounded medications are not FDA-approved.
Visit Wellorithm Paid linkDiscontinuation is a legitimate clinical decision — but it deserves the same planning as initiation. Talk to your prescriber about a monitoring plan before your last dose, not after regain begins.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.